SCHEMBL1329786

SCHEMBL1329786

C(#Cc1ccnc2[nH]ccc12)c1ncccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 4/20 0.47
AXL P30530 2/20 0.47
LRRK2 Q5S007 2/20 0.46
AURKB Q96GD4 2/20 0.46
IGF1R P08069 2/20 0.46
DYRK1B Q9Y463 2/20 0.46
IKBKB O14920 1/20 0.46
CHUK O15111 1/20 0.46
DAPK3 O43293 1/20 0.46
JAK2 O60674 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
FGFR1 P11362 1/20 0.46
PRKACA P17612 1/20 0.46
FLT1 P17948 1/20 0.46
LTK P29376 1/20 0.46
GRK5 P34947 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1328230 0.83 PRKCI (0.51) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL857174 0.82 JAK2 (0.53) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL1328989 0.81 PRKCI (0.45) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL12125679 0.80 IKBKB (0.46) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL1330601 0.80 LRRK2 (0.50) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL1328408 0.80 ROCK1 (0.46) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL15941143 0.80 NUDT1 (0.47) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL1328069 0.79 PRKCI (0.46) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL24678723 0.78 PRKCI (0.50) PRKCIAXLLRRK2AURKBIGF1R
SCHEMBL30084214 0.78 PRKCI (0.50) PRKCIAXLLRRK2AURKBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-11-17 US claimed
EP-2231282-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-09-29 EP claimed
WO-2009094123-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-07-30 WO claimed
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282056-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP3K19, MAP3K20, MAP3K1 PRKCI 46/4885AXL 383/4885LRRK2 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.